Arthur Lahr, a former executive of Crucell, has been named chief operating officer and chief executive-designate at Kiadis Pharma NV, effective 1 January 2017. Mr Lahr will succeed Manfred Rüdiger who has led the cell therapy company since 2011. Kiadis’ lead product, which is an adjunct to a haematopoietic stem cell transplant, is poised to enter a pivotal Phase 3 clinical trial.
Mr Lahr was chief strategy officer and a member of the management committee of Crucell from 2001 until the company’s acquisition by Johnson & Johnson Inc in 2011. Before this, he was a consultant at McKinsey & Company. He holds an MSc in applied physics from the University of Delft in the Netherlands and an MBA from the INSEAD business school.
Kiadis announced the appointment on 8 December 2016.
Copyright 2016 Evernow Publishing Ltd